News

Bayer AG's stock tumbled significantly on Friday, closing down 6.46 percent at €23.25 after the company announced plans to seek shareholder approval for a substantial capital authorization. At the

Darmstadt-based pharmaceutical and technology company Merck is showing initial signs of technical stabilization following an extended period of weakness. Currently trading at approximately €135, the

Eli Lilly has reported significant progress with its medication Ebglyss for moderate to severe atopic dermatitis. At the American Academy of Dermatology annual meeting in Orlando, the company

Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New

Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares

Abbott Laboratories is experiencing notable stock market activity as multiple senior executives recently divested portions of their holdings. Former Executive Vice President Andrea F. Wainer sold

Veeva Systems has introduced Commercial Pulse, a new data offering designed to enhance market segmentation and targeting for life sciences companies. This solution provides quarterly updates on

Vertex Pharmaceuticals Inc. has seen significant insider selling activity recently, with top executives divesting substantial shareholdings while the company's stock enjoys impressive performance

Teva Pharmaceutical Industries Ltd. continues to strengthen its global market position through strategic access initiatives for essential medications. The company has made significant progress

Pharmaceutical giant Eli Lilly and Company, now the world's most valuable pharma corporation with a market capitalization exceeding $855 billion, announced Wednesday it will invest an additional $27

Morgan Stanley's optimistic outlook for Gilead Sciences' HIV prevention medication Lenacapavir has positioned the company for significant market advancement. The drug, anticipated to receive FDA

Eli Lilly continues to demonstrate remarkable market performance, posting an impressive 32 percent revenue growth over the past twelve months. The pharmaceutical giant's robust financial health is

Die Edwards Lifesciences Corporation, ein führender Anbieter von Herz-Kreislauf-Produkten, wird am 4. März 2025 an der TD Cowen Healthcare Conference teilnehmen. Das Unternehmen mit einer aktuellen

The healthcare insurance giant Unitedhealth experienced a significant market setback on Friday as its stock plummeted more than 7%, deepening the company's recent struggles. The sharp decline came

Die Edwards Lifesciences Aktie präsentiert sich in der aktuellen Marktphase weitgehend stabil, mit einem aktuellen Kurs von 70,33 EUR. Der US-amerikanische Spezialist für

The Swiss pharmaceutical giant has experienced a notable stock price increase following the unveiling of its groundbreaking DNA sequencing technology. The innovative method, dubbed "Sequencing by

A recent study by Teva Pharmaceuticals Europe reveals concerning trends in the European pharmaceutical landscape, highlighting significant market consolidation in critical generic medications. The

Unitedhealth Group experienced a significant market setback on Friday as its shares plummeted nearly 9% following revelations of a Department of Justice investigation. The probe centers on the